stockrow
Saturday 7 November 2026
Export BIORQ’s income statement to Excel — free account
Biora Therapeutics, Inc.
BIORQ Healthcare Biotechnology
Biora Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $4,000.00, down 98.7% from fiscal 2022.
0.00
0.00
NaN
Follow BIORQ
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM Sep ’24 | Trend | 10 yrs | 2024e | 2025e | 2026e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 128 | 144 | 0 | 1 | 0 | 0 | 1 | (87.4%) | 1 | 0 | 0 | +84.2% | |
| Gross margin, % | — | — | — | — | 28.05 | 30.21 | 100.00 | 100.00 | 100.00 | 100.00 | 85.79 | +72.0 pt | ||||||
| EBT | — | — | — | — | (124) | (149) | (143) | (179) | (49) | (124) | (36) | +0.1% | ||||||
| EBT margin, % | — | — | — | — | (96.78) | (103.30) | (88,035.80) | (14,325.58) | (16,147.54) | (3,110,600.00) | (3,996.87) | (3,110,503.2) pt | ||||||
| Net income | — | — | — | 0 | (129) | (148) | (193) | (247) | (38) | (124) | (32) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 69.30 | 7,383.85 | 1.47 | 3.24 | 0.40 | 0.00 | 0.02 | (87.1%) | |||||
| Earnings | — | — | — | — | (69.92) | (11,716.30) | (1,752.50) | (642.50) | (50.00) | (78.70) | (10.82) | +2.4% | ||||||
| Cash flow | — | — | — | — | (35.27) | (5,442.26) | (1,505.40) | (435.48) | (84.37) | (30.75) | (1.26) | (2.7%) | ||||||
| Capex | — | — | — | — | 0.00 | (191.03) | (35.16) | (2.22) | (1.04) | (0.06) | (0.01) | n/m | ||||||
| Free cash flow | — | — | — | — | (35.27) | (5,633.28) | (1,540.55) | (437.70) | (85.41) | (30.81) | (1.26) | (2.7%) | ||||||
| Book value | — | — | — | — | (20.02) | (4,301.23) | (971.79) | (220.95) | (133.97) | (64.30) | (2.92) | +26.3% | ||||||
| Shares, m | — | — | — | — | 2 | 0 | 0 | 0 | 1 | 2 | 11 | (3.1%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.58 | 0.58 | 7.64 | 278.35 | 58.83 | 338.67 | 0.00 | 114.1 | ||||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | 1.12 | 1.12 | 9.63 | 308.82 | 380.85 | 649.91 | 67.44 | 225.2 | ||||||
| EV/FCF | — | — | — | — | (0.89) | (0.89) | (1.95) | (2.29) | (1.78) | (1.31) | (1.31) | (1.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (65) | (106) | (166) | (167) | (64) | (48) | (46) | (5.7%) | |||||
| Capex | — | — | — | — | (5) | (4) | (4) | (1) | (1) | 0 | 0 | (54.7%) | ||||||
| Free cash flow | — | — | — | — | (65) | (110) | (170) | (168) | (65) | (49) | (46) | (5.7%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 11 | (26) | 54 | 37 | 15 | (44) | (115) | n/m | |||||
| Net debt | — | — | — | — | 4 | (29) | 68 | 38 | 98 | 31 | 17 | +53.9% | ||||||
| Shareholders’ equity | — | — | — | — | (37) | (84) | (107) | (85) | (102) | (101) | (107) | +22.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (221.84) | (209.81) | (150.52) | (187.95) | (47.00) | (292.93) | (128.19) | (71.1) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | 213.45 | 378.33 | 201.91 | 257.76 | 40.75 | 121.86 | 27.98 | (91.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 674 | 649 | 124 | 54 | 58 | — | (45.8%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.21 | 0.00 | 0.01 | 0.01 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2023 · latest quarter Sep 2024 · fundamentals updated 26 Oct 2026
Biora Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DCOY Decoy Therapeutics Inc | $2.7M | — (loss-making) | — (loss-making) | −84.61% (below 0%: shrinking) | n/m | −212.47% (below 0%: shrinking) | 100.00% | (1,055.98%) | Compare |
| NRSN NeuroSense Therapeutics Ltd. | $2.6M | — (loss-making) | — | — | n/m | −23,458.82% (below 0%: shrinking) | — | 0.00% | Compare |
| EOCN Eocene Ltd. | $2.6M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −67.74% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BIORQ Biora Therapeutics, Inc. | $2.5M | — (loss-making) | — (loss-making) | +1,500.00% (above 0%: growing) | n/m | +20.72% (above 0%: growing) | 100.00% | (50,709.38%) | |
| CLDI Calidi Biotherapeutics, Inc. | $2.5M | — (loss-making) | — | — | n/m | +11.16% (above 0%: growing) | — | 0.00% | Compare |
| WINT Windtree Therapeutics, Inc. | $2.4M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +1.12% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VIVS VivoSim Labs, Inc. | $2.3M | — (loss-making) | — (loss-making) | −51.35% (below 0%: shrinking) | n/m | +17.87% (above 0%: growing) | 100.00% | (15,327.78%) | Compare |
| HCWB HCW Biologics Inc. | $2.3M | — (loss-making) | — (loss-making) | +1,954.55% (above 0%: growing) | n/m | −20.84% (below 0%: shrinking) | (69.25%) | (2,335.03%) | Compare |
| APVO Aptevo Therapeutics Inc. | $2.3M | — (loss-making) | — (loss-making) | +28.62% (above 0%: growing) | n/m | +23.11% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $2.4M | — | — | −67.98% | — | −9.86% | 0.00% | 0.00% |